/
Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company. Medtronic was founded in 1949 and today serves healthcare systems, physicians, clinicians, and patients in more than 150 countries worldwide.
$83.20
$0.36 (-0.43%)
EOD Jul 17, 2026
17.78% operating margin is respectable but not wide. ROIC at 6.61%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 8.4%, steady but not accelerating.
Even for strong businesses, today's 22x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
22.3x earnings, 19.8x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$36.36B
▲ +8.4% YoY
Net Income (TTM)
$4.80B
▲ +3.0% YoY
Op. Margin
17.78%
ROIC
6.61%
▲ +0.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$5.43B
▲ +4.6% YoY
Op. Cash Flow (TTM)
$7.33B
▲ +4.1% YoY
Net Debt
$19.99B
Cash & Equiv.
$9.22B
5Y CAGR: +3.8%
5Y CAGR: +2.1%
Continue Research
At a P/E of 22.3 and a price-to-free-cash-flow of 19.8, Medtronic (MDT) trades above a two-stage DCF intrinsic value of about $57.48 per share, so at $83.20 the stock looks overvalued (30.9% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Medtronic scores 63/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 3.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $57.48 per share for MDT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $43.11. At today's $83.20, that puts the stock about 30.9% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Medtronic scores 63 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 17.8% operating margin and a 6.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Medtronic pays a regular dividend of about $2.83 per share per year (typically in quarterly installments), a yield of roughly 3.4% at the current price. That is a payout ratio of about 75.8% of earnings, so the dividend is covered, with less cushion. Medtronic has grown the dividend at roughly 1.8% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For MDT's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. MDT currently trades above its estimated intrinsic value and scores 63/100 on quality (solid). It also yields about 3.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.